Document Detail

Combination regimens with statin, niacin, and intestinally active LDL-lowering drugs: alternatives to high-dose statin therapy?
MedLine Citation:
PMID:  20625257     Owner:  NLM     Status:  MEDLINE    
PURPOSE OF REVIEW: To summarize recent studies on combination regimens that employ a statin with added niacin, ezetimibe, and/or bile acid sequestrants, and to understand the implications of these studies for clinical practice. RECENT FINDINGS: Combinations of statin, niacin, and/or intestinally active LDL-lowering drug have demonstrated safety and favorable effects on plasma low and high-density lipoproteins. Niacin and bile acid sequestrants appear to exert beneficial effects on atherosclerotic lesions, whereas results with ezetimibe are uncertain. Moreover, the use of niacin and bile acid sequestrants is supported by clinical outcome results from large monotherapy trials and small combination therapy trials. Three large randomized trials currently are evaluating clinical outcomes with the addition of niacin or ezetimibe to statin treatment. SUMMARY: Until the results of ongoing trials are known, it is reasonable to favor the use of niacin and bile acid sequestrants in combination with statins, based on safety and efficacy with regard to effects on lipoproteins, atherosclerotic lesions, and, to a limited extent, clinical outcomes. The effect of ezetimibe on carotid atherosclerosis is indeterminate, but ezetimibe can be reasonably added to statin therapy as a secondary option for LDL-lowering.
John R Guyton
Related Documents :
2948527 - Isolation and partial characterization of apolipoprotein (a) from human lipoprotein (a).
2669667 - Effects of modest doses of omega-3 fatty acids on lipids and lipoproteins in hypertrigl...
7065277 - Hydrolysis of sarcolemma by lysosomal lipases and inhibition by chlorpromazine.
20336917 - Serum fatty acids and cardiovascular risk factors in sudden sensorineural hearing loss:...
15465677 - Biochemical dynamics of spermatogenesis and oogenesis in eledone cirrhosa and eledone m...
12062417 - Aerobic and anaerobic nad+ metabolism in saccharomyces cerevisiae.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current opinion in lipidology     Volume:  21     ISSN:  1473-6535     ISO Abbreviation:  Curr. Opin. Lipidol.     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-07-13     Completed Date:  2010-10-08     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9010000     Medline TA:  Curr Opin Lipidol     Country:  England    
Other Details:
Languages:  eng     Pagination:  372-7     Citation Subset:  IM    
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cardiovascular System / drug effects
Drug Combinations
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects,  pharmacology,  therapeutic use*
Intestines / drug effects*
Lipoproteins, LDL / blood,  metabolism*
Niacin / adverse effects,  pharmacology,  therapeutic use*
Reg. No./Substance:
0/Drug Combinations; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Lipoproteins, LDL; 59-67-6/Niacin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Fibrates: no ACCORD on their use in the treatment of dyslipidaemia.
Next Document:  Current world literature.